Optimizing a candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay

Journal of Clinical Microbiology

Volumn 49, Issue 4, 2011, Pages 1426-1433

  Nett, Jeniel E ^a,c   Cain, Michael T ^b   Crawford, Kyler ^b   Andes, David R ^a,b,c,d  

^a Departments of Microbiology and Immunology   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^d UW Medical Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; HYDROGEN PEROXIDE; TETRAZOLIUM;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS GROWTH; INCUBATION TIME; MICROTITER PLATE ASSAY; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SCREENING TEST; STRAIN DIFFERENCE;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TETRAZOLIUM SALTS;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS;

EID: 79953857463     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02273-10     Document Type: Article

References (39)

1. Al-Fattani, M. A., and L. J. Douglas. 2006. Biofilm matrix of Candida albicans and Candida tropicalis: Chemical composition and role in drug resistance. J. Med. Microbiol. 55:999-1008. (Pubitemid 44215557)
2. Andes, D., et al. 2004. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect. Immun. 72:6023-6031. (Pubitemid 39303717)
3. Baillie, G. S., and L. J. Douglas. 1998. Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob. Agents Chemother.42:1900-1905. (Pubitemid 28363067)
4. Chandra, J., et al. 2001. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J. Bacteriol. 183: 5385-5394. (Pubitemid 32802612)
5. Chandra, J., P. K. Mukherjee, and M. A. Ghannoum. 2008. In vitro growth and analysis of Candida biofilms. Nat. Protoc. 3:1909-1924.
6. Davis, D., R. B. Wilson, and A. P. Mitchell. 2000. RIM101-dependent and -independent pathways govern pH responses in Candida albicans. Mol. Cell. Biol. 20:971-978. (Pubitemid 30044234)
7. Hawser, S. 1996. Adhesion of different Candida spp. to plastic: XTT formazan determinations. J. Med. Vet. Mycol. 34:407-410. (Pubitemid 26420099)
8. Hawser, S. P., and L. J. Douglas. 1995. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 39: 2128-2131.
9. Hawser, S. P., H. Norris, C. J. Jessup, and M. A. Ghannoum. 1998. Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]- 2H-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J. Clin. Microbiol. 36:1450-1452. (Pubitemid 28208050)
10. Honraet, K., E. Goetghebeur, and H. J. Nelis. 2005. Comparison of three assays for the quantification of Candida biomass in suspension and CDC reactor grown biofilms. J. Microbiol. Methods 63:287-295. (Pubitemid 41597373)
11. Hornby, J. M., et al. 2001. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl. Environ. Microbiol. 67:2982-2992. (Pubitemid 33644762)
12. Jacobson, M. J., K. E. Steckelberg, K. E. Piper, J. M. Steckelberg, and R. Patel. 2009. In vitro activity of micafungin against planktonic and sessile Candida albicans isolates. Antimicrob. Agents Chemother. 53:2638-2639.
13. Jin, Y., L. P. Samaranayake, Y. Samaranayake, and H. K. Yip. 2004. Biofilm formation of Candida albicans is variably affected by saliva and dietary sugars. Arch. Oral Biol. 49:789-798. (Pubitemid 39081809)
14. Kuhn, D. M., M. Balkis, J. Chandra, P. K. Mukherjee, and M. A. Ghannoum. 2003. Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J. Clin. Microbiol. 41:506-508. (Pubitemid 36098635)
15. Kuhn, D. M., and M. A. Ghannoum. 2004. Candida biofilms: Antifungal resistance and emerging therapeutic options. Curr. Opin. Investig. Drugs 5:186-197.
16. Kumamoto, C. A., and M. D. Vinces. 2005. Alternative Candida albicans lifestyles: Growth on surfaces. Annu. Rev. Microbiol. 59:113-133. (Pubitemid 41507426)
17. LaFleur, M. D., C. A. Kumamoto, and K. Lewis. 2006. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob. Agents Chemother. 50:3839-3846. (Pubitemid 44684901)
18. Melo, A. S., A. L. Colombo, and B. A. Arthington-Skaggs. 2007. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob. Agents Chemother. 51:3081-3088. (Pubitemid 350067512)
19. Mowat, E., et al. 2008. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. J. Antimicrob. Chemother. 62:1281-1284.
20. Mukherjee, P. K., J. Chandra, D. M. Kuhn, and M. A. Ghannoum. 2003. Mechanism of fluconazole resistance in Candida albicans biofilms: Phasespecific role of efflux pumps and membrane sterols. Infect. Immun. 71:4333-4340. (Pubitemid 36919897)
21. Nett, J., et al. 2007. Putative role of β-1,3 glucans in Candida albicans biofilm resistance. Antimicrob. Agents Chemother. 51:510-520. (Pubitemid 46185268)
22. Nett, J. E., K. Crawford, K. Marchillo, and D. R. Andes. 2010. Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob. Agents Chemother. 54:3505-3508.
23. Nett, J. E., K. M. Guite, A. Ringeisen, K. A. Holoyda, and D. R. Andes. 2008. Reduced biocide susceptibility in Candida albicans biofilms. Antimicrob. Agents Chemother. 52:3411-3413.
24. Nett, J. E., H. Sanchez, M. T. Cain, and D. R. Andes. 2010. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J. Infect. Dis. 202:171-175.
25. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
26. Perumal, P., S. Mekala, and W. L. Chaffin. 2007. Role for cell density in antifungal drug resistance in Candida albicans biofilms. Antimicrob. Agents Chemother. 51:2454-2463. (Pubitemid 47047324)
27. Ramage, G., S. Bachmann, T. F. Patterson, B. L. Wickes, and J. L. Lopez- Ribot. 2002. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J. Antimicrob. Chemother. 49:973-980. (Pubitemid 34692891)
28. Ramage, G., and J. L. Lopez-Ribot. 2005. Techniques for antifungal susceptibility testing of Candida albicans biofilms. Methods Mol. Med. 118:71-79.
29. Ramage, G., S. P. Saville, D. P. Thomas, and J. L. Lopez-Ribot. 2005. Candida biofilms: An update. Eukaryot. Cell 4:633-638. (Pubitemid 40600417)
30. Ramage, G., S. P. Saville, B. L. Wickes, and J. L. Lopez-Ribot. 2002. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl. Environ. Microbiol. 68:5459-5463. (Pubitemid 35265681)
31. Ramage, G., K. Vande Walle, B. L. Wickes, and J. L. Lopez-Ribot. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479. (Pubitemid 32801898)
32. Ramage, G., K. VandeWalle, J. L. Lopez-Ribot, and B. L. Wickes. 2002. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol. Lett. 214:95-100. (Pubitemid 35245528)
33. Ramage, G., K. Vandewalle, B. L. Wickes, and J. L. Lopez-Ribot. 2001. Characteristics of biofilm formation by Candida albicans. Rev. Iberoam. Micol. 18:163-170. (Pubitemid 34116636)
34. Rementeria, A., et al. 2007. Comparison of tablet and disk diffusion methods for fluconazole and voriconazole in vitro activity testing against clinical yeast isolates. J. Chemother. 19:172-177. (Pubitemid 46697737)
35. Richard, M. L., C. J. Nobile, V. M. Bruno, and A. P. Mitchell. 2005. Candida albicans biofilm-defective mutants. Eukaryot. Cell 4:1493-1502. (Pubitemid 41176703)
36. Samaranayake, Y. H., J. Ye, J. Y. Yau, B. P. Cheung, and L. P. Samaranayake. 2005. In vitro method to study antifungal perfusion in Candida biofilms. J. Clin. Microbiol. 43:818-825. (Pubitemid 40256040)
37. Seneviratne, C. J., L. J. Jin, Y. H. Samaranayake, and L. P. Samaranayake.2008. Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms. Antimicrob. Agents Chemother. 52:3259-3266.
38. Tellier, R., M. Krajden, G. A. Grigoriew, and I. Campbell. 1992. Innovative endpoint determination system for antifungal susceptibility testing of yeasts. Antimicrob. Agents Chemother. 36:1619-1625.
39. Uppuluri, P., J. Nett, J. Heitman, and D. Andes. 2008. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob. Agents Chemother. 52:1127-1132. (Pubitemid 351358397)